The contributory role of GSK3β in hypertension exacerbating atherosclerosis by regulating the OMA1/PGC1α pathway
Apoptosis · 2025
DOI: 10.1007/s10495-024-02029-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, 2025. Verfasst von Hongjia Bao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian, 1…. Hauptthemen laut MEDLINE: Atherosclerosis, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Hypertension, Glycogen Synthase Kinase 3 beta. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis is closely related to endothelial dysfunction and hypertension. GSK3β is a critical regulator in atherosclerosis. This study was carried out to investigate the effects of GSK3β on hypertension exacerbating atherosclerosis in vitro and in vivo. L-NAME + HFD-ApoE-/- mice were used for this study for 12 weeks, and their endothelial dysfunction and inflammation were analyzed. Oil red O and H&E staining revealed that treatment with LiCl, an inhibitor of GSK3β, reduced atherosclerotic lesions and lipid accumulation. The levels of lipid homeostasis and oxidation stress were attenuated following LiCl administration. LiCl-treated ApoE-/- mice showed lowered blood pressure. LiCl also suppressed the expressions of Drp1, Bax, ICAM1, VCAM1 and TNF-α compared to HFD + L-NAME induced mice and oxLDL + L-NAME-treated Human aorta endothelial cell line(HAECs). LiCl treatment increased the expressions of MFN2 and Bcl2. Mitotracker-red, MitoSOX and JC-1 staining indicated that LiCl treatment reduced mitochondrial division and ROS production, increased mitochondrial ΔΨm compared to oxLDL + L-NAME-treated HAECs. The expression of OMA1 was decreased by LiCl treatment, while PGC1α expression was increased. In HAECs, we found that OMA1 knockdown increased mitochondrial function and the expression of PGC1α. We also demonstrated LiCl increased OMA1 ubiquitination compared with the Control group, thus decreased OMA1 expression. Furthermore, siOMA1 antagonized the increased protein expressions of ICAM1, VCAM1, TNF-α, Bax and Drp1, decreased the protein expressions of Bcl2 and MFN2 by siPGC1α. Taken together, we demonstrated that GSK3β could play a contributory role in hypertension exacerbating atherosclerosis by regulating the OMA1/PGC1α pathway and inhibiting mitochondrial function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian, 116044, China.
- Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian, 116044, China. sunhuijun@dmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bao, H., Wang, C., Jin, Y., Meng, Q., Wu, J., Liu, Q., & Sun, H. (2025). The contributory role of GSK3β in hypertension exacerbating atherosclerosis by regulating the OMA1/PGC1α pathway. Apoptosis. https://doi.org/10.1007/s10495-024-02029-1
Vancouver
Bao H, Wang C, Jin Y, Meng Q, Wu J, Liu Q, et al. The contributory role of GSK3β in hypertension exacerbating atherosclerosis by regulating the OMA1/PGC1α pathway. Apoptosis. 2025. doi:10.1007/s10495-024-02029-1
BibTeX
@article{Bao2025,
author = {Bao, Hongjia and Wang, Changyuan and Jin, Yue and Meng, Qiang and Wu, Jingjing and Liu, Qi and Sun, Huijun},
title = {The contributory role of GSK3β in hypertension exacerbating atherosclerosis by regulating the OMA1/PGC1α pathway},
journal = {Apoptosis},
year = {2025},
doi = {10.1007/s10495-024-02029-1}
}
EUVIMED